# Service Corporation International (SCI) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/SCI/thesis · /stocks/SCI/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: SCI
company: Service Corporation International
step: 04
title: Financial Quality & Adversarial Research Sweep
date: 2026-05-27
---

### Step 04 — Financial Quality & Adversarial Research Sweep: SCI

#### 1. Income Statement Quality Assessment

##### 1a. Revenue Recognition Complexity

SCI's revenue recognition is nuanced and creates legitimate complexity — not manipulation, but analysts must understand it [S1]:

1. **Preneed revenue deferral**: Cash collected from preneed contracts does NOT flow through revenue at sale. Revenue is only recognized upon service delivery. This creates a large deferred revenue liability ($1.78B on-balance-sheet) and $17B in trust-backed future obligations.
2. **Trust fund income**: Investment returns on preneed trusts are recognized as revenue in the period earned. This creates volatility tied to capital markets (rising in bull markets, declining in bear markets).
3. **Preneed merchandise**: Cemetery merchandise (vault, marker) is recognized when installed, not when sold. This creates timing differences.

**Assessment**: Revenue recognition is conservative and well-established. Deferred revenue model protects consumers and creates strong future visibility.

##### 1b. COVID Distortion

FY2021 results ($4.14B revenue, $803M net income, $4.72 EPS) are materially distorted by elevated COVID-related deaths. Analysts using 2021 as a baseline for trend analysis will overstate SCI's organic growth. The correct baseline is 2022–2025 normalized results:
- Revenue: $4.1–$4.3B (2022–2025 range)
- Gross margin: 26–28% (vs. COVID-inflated 31.9% in 2021)
- Net income: $519–$565M (excluding COVID windfall)

**Adjustment**: Exclude 2021 when calculating 3-year averages for margin analysis.

##### 1c. EPS vs. Net Income Divergence

EPS grew from $3.53 (2022–2023) to $3.80 (2025) while net income was roughly flat (~$540M). The growth is entirely buyback-driven — shares outstanding declined from 153.9M (2022) to 139.7M (2025), a 9.2% reduction. **EPS growth investors should note this is financial engineering, not earnings growth** — though disciplined buybacks at these multiples do create value.

#### 2. Balance Sheet Quality Assessment

##### 2a. Debt and Leverage

| Metric | 2023 | 2024 | 2025 |
|--------|------|------|------|
| Total Long-Term Debt | $4,712M | $4,835M | $5,140M |
| Cash | $222M | $219M | $244M |
| Net Debt | ~$4,490M | ~$4,616M | ~$4,896M |
| EBITDA | $1,262M | $1,263M | $1,327M |
| Net Debt / EBITDA | 3.56x | 3.66x | 3.69x |

**Assessment**: Leverage is elevated but manageable given the predictability of SCI's OCF ($900M+ annually). The company has consistently maintained ~3.5–4.0x leverage through the cycle. Investment-grade credit rating (Moody's, S&P) allows low-cost debt financing.

**Risk**: Leverage is rising (~$400M net debt increase in 2025 vs. 2024). At some point, this limits buyback capacity or requires asset sales.

##### 2b. Goodwill Quality

Goodwill increased to $2,169M (2025) from $1,915M (2021), reflecting acquisitions. As a % of total equity: ~132% (goodwill exceeds book equity). This is elevated but common for serial acquirers in service businesses where intangibles (brand, licenses, preneed customer relationships) dominate asset value.

**Key question**: Has SCI overpaid for acquisitions? See Step 07 for M&A deep dive.

##### 2c. Trust Fund Assets — Largest Balance Sheet Item

SCI's $18.7B total assets (2025) include ~$8.2B in preneed trust investments [S2]. These are offset by corresponding preneed trust liabilities — they are not "free" assets. Net position of trust assets vs. trust liabilities matters for cash generation analysis.

Trust investments: fixed income + equities managed by third parties. Market value fluctuations affect recognized trust income but not balance sheet principal for GAAP.

#### 3. Cash Flow Quality Assessment

##### 3a. Operating Cash Flow vs. Net Income (Reconciliation)

| Year | Net Income | OCF | OCF/NI Ratio | Quality |
|------|-----------|-----|-------------|---------|
| 2022 | $565M | $826M | 1.46x | Good |
| 2023 | $537M | $869M | 1.62x | Good |
| 2024 | $519M | $945M | 1.82x | Very Good |
| 2025 | $543M | $943M | 1.74x | Very Good |

OCF consistently exceeds net income by a significant margin, driven by non-cash items (depreciation ~$350M, trust income timing). This is a quality indicator — earnings are being backed by real cash.

##### 3b. Free Cash Flow Analysis

| Year | OCF | CapEx | FCF | FCF Margin |
|------|-----|-------|-----|-----------|
| 2023 | $869M | $362M | $507M | 12.4% |
| 2024 | $945M | $374M | $571M | 13.6% |
| 2025 | $943M | $389M | $554M | 12.9% |

*Note: CapEx from StockAnalysis (PaymentsToAcquireProductiveAssets); 2025 CapEx of $388.6M confirmed in press release*

FCF yield at current $10.6B market cap: ~5.2% (2025 FCF). This is modestly attractive for a high-quality defensive business.

**CapEx intensity**: ~9% of revenue in maintenance + growth CapEx. Company guides to ~$325M maintenance CapEx for 2026. The ~$65M above maintenance in 2025 represents growth/cemetery development.

#### 4. Adversarial Research Sweep

*Examining short theses, lawsuits, investigations, and bear case arguments*

##### 4a. California AG Settlement (2024)

**Finding**: California Attorney General reached a $23M settlement with SCI affiliates for violations of Unfair Competition Law and False Advertising Law related to preneed cremation marketing. Alleged misleading sales practices around direct cremation packages [S3].

**Assessment**: $23M is ~2.5% of a single year's OCF — immaterial financially. However, it raises questions about SCI's aggressive preneed sales practices. Company agreed to comprehensive injunctive relief and full customer restitution. **Risk to watch**: Similar state investigations in FL, TX, NY where SCI has large concentration.

##### 4b. Preneed Marketing Controversy — Recurring Pattern

Industry critics and state regulators periodically investigate death care companies for high-pressure preneed sales tactics targeting elderly consumers. SCI has faced:
- State-level investigations in multiple jurisdictions historically
- Consumer complaint databases show recurring issues with preneed sales counselor conduct
- FTC Funeral Rule complaints

**Assessment**: Systemic risk, not idiosyncratic to one event. Manageable if company maintains compliance culture.

##### 4c. Bear Case: Cremation Revenue Compression

The most serious structural bear argument: cremation mix will rise to 80%+ by 2045, compressing revenue per call by 40–50% over two decades. Even with pricing discipline, lower-cost cremation fundamentally changes unit economics.

**Counter**: (1) SCI is pricing cremation profitably; (2) cemetery remains burial/memorialization focused even for cremated remains; (3) preneed pricing locks in today's rates; (4) volume tailwind partially offsets per-call compression.

**Assessment**: Real, long-term headwind. Not existential, but limits revenue growth potential. Market appears to have appropriately discounted this.

##### 4d. Debt Accumulation Concern

Net debt grew from ~$3.7B (2020) to ~$4.9B (2025) — a $1.2B increase over 5 years while the company has generated ~$4.5B in cumulative OCF. The debt growth is explained by $2.9B in buybacks, $900M in dividends, and $560M in acquisitions — net $4.4B returned/deployed vs. $4.5B OCF. Leverage is rising but is a deliberate financial policy, not operational deterioration.

**Assessment**: At 3.9x Net Debt/EBITDA, SCI is at the high end of management's target. A recession or investment-grade credit downgrade could increase interest costs. Watch if Net Debt/EBITDA approaches 4.5x.

##### 4e. SCI Not a Growth Story

Short sellers and value skeptics point out: SCI's revenue has grown just 4.0% total from 2022 to 2025 ($4.11B → $4.31B), essentially flat. Post-COVID normalization means the company faces a multi-year period of slow revenue growth. EPS "growth" is entirely financial engineering (buybacks).

**Assessment**: Accurate. SCI is a capital allocator and income stock, not a growth stock. The bullish case depends on: (1) demographic tailwind materializing 2028+; (2) pricing power continuing; (3) buybacks at current low P/E accreting to value. Investors expecting revenue growth will be disappointed.

#### 5. Accounting Policy Notes

| Policy | SCI Treatment | Industry Norm |
|--------|-------------|---------------|
| Preneed revenue recognition | Conservative deferred model | Same across industry |
| Trust fund accounting | Per-state trust regulations | Same |
| Goodwill amortization | None (GAAP, tests for impairment) | Same |
| Depreciation | Straight-line on PP&E | Same |
| SBC | Equity-based; $18M/yr (minimal) | Same |

**No material accounting concerns identified.** SCI's financials are clean and consistent.

#### 6. Financial Quality Score

| Dimension | Score (1–5) | Notes |
|-----------|------------|-------|
| Revenue quality | 4 | Deferred model is conservative; trust income adds some noise |
| Earnings quality | 4 | OCF > NI consistently; minimal accruals manipulation |
| Balance sheet quality | 3 | Elevated leverage; goodwill large relative to equity |
| Cash flow quality | 5 | FCF consistently $500–$575M; well-covered dividend |
| Accounting transparency | 4 | Complex preneed reporting but well-disclosed |
| **Overall** | **4/5** | **High-quality business; leverage is main risk** |

#### 7. Source Index

| ID | Source |
|----|--------|
| S1 | StockAnalysis.com income statement + SCI 10-K revenue recognition notes |
| S2 | XBRL data: trust investments ($8.2B), total assets ($18.7B) — 2025 |
| S3 | California AG settlement — Tavily web search (2026-05-27) |
| S4 | Q4 2025 Press Release — OCF $943M, capex $388.6M, buybacks $461M |
| S5 | XBRL: Net income, OCF (2022–2025); StockAnalysis FCF series |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/SCI/fundamental

## Navigation

- Overview: /stocks/SCI
- Financials (this page): /stocks/SCI/financials
- Thesis: /stocks/SCI/thesis
- Investment Memo: /stocks/SCI/memo
- Coverage universe: /stocks